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Abstract
Background: Dedifferentiated endometrioid adenocarcinoma (DEAC) is rare and is known to be more aggressive
than high-grade endometrioid carcinoma. Differentiating between the two is important to provide appropriate
treatment for patients.
Case presentation: This is a retrospective study including four cases of DEAC of the uterus, which was diagnosed
and treated in our Obstetrics and Gynecology department between January 2013 and December 2015. Clinical,
pathological, and immunohistochemical staining features are discussed. Each tumor was composed of
undifferentiated carcinoma (UC) and low-grade endometrioid carcinoma with abrupt transition between them. Two
patients showed recurrence or progression within one month postoperatively and died at the last follow-up. An
immunohistochemical study showed PAX-8, ER, PR, and E-cadherin expression in UC component.
Conclusions: DEAC should not be underdiagnosed as conventional endometrioid adenocarcinoma due to its
fulminant clinical course. Therefore, UC, including DEAC, should be further categorized to provide intensive
treatment to improve patient survival.
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Background
Endometrial carcinoma is the most common gynecologic
malignancy in developed countries [1]. It comprises several
pathological subtypes, such as endometrioid, mucinous,
clear cell, mixed cell, undifferentiated, and dedifferentiated
carcinoma[2]. The last two entities are recently defined to
distinguish them from other less aggressive tumors, there-
fore, providing proper treatment for patients.
Undifferentiated carcinoma (UC) of the endometrium is
defined as a malignant neoplasm with no differentiation.
It displays solid patternless growth and has worse clinical
outcome than high-grade endometrioid adenocarcinoma.
It is often observed admixed with differentiated endome-
trioid carcinoma (grade 1/2), which is referred to as dedif-
ferentiated endometrioid adenocarcinoma (DEAC). The
biologic features of DEAC are known to be determined by
UC component even when this component represents
20% of the entire neoplasms, thus, with aggressive
outcome [3].
In the current International Federation of Obstetrics
and Gynecology (FIGO) grading system of endometrioid
adenocarcinoma, tumors are graded by the proportion
of solid components within a tumor, without further
details on the histologic features of solid areas, resulting
in misdiagnosis of DEAC as FIGO grade 2 or 3 endome-
trioid carcinoma. However, differentiating between the
two is important in providing appropriate treatment
options for patients. The present study reports four
cases diagnosed with DEAC and reviews the literatures
updated on the clinical, radiological, and pathological
DEAC characteristics of the uterus.
Case presentation
This is a retrospective study including four cases of
DEAC of the uterus, which was diagnosed and treated in
our Obstetrics and Gynecology department between
January 2013 and December 2015. During this period,
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155 cases of endometrial carcinoma were initially diag-
nosed and of which four patients (2.6%) were diagnosed
with DEAC in our hospital. Clinical, pathological, and
immunohistochemical staining features are outlined
below and in Table 1, Table 2, and Table 3.
Case 1
A 77-year-old woman (body mass index [BMI],
19.6 kg/m2) presented with 1 week postmenopausal
bleeding, which was preceded by vaginal spotting for
1 year and concomitant genital itching that had
continued for 2 weeks. Transvaginal ultrasound re-
vealed abnormally thickened endometrium (1.47 cm)
and biopsy was recommended, but she refused. After
2 weeks, follow-up ultrasonography showed remark-
ably increased endometrium thickness (2.36 cm) with
a 7 cm mixed-echoic lesion within the endometrial
cavity. Endometrial curettage revealed poorly differen-
tiated carcinoma. Magnetic resonance imaging (MRI)
showed 8.6 × 3.7 cm heterogeneously enhanced mass
on contrast-enhanced T1-weighted images (CET1WI)
(Fig. 1a). In addition, tumor involvement of the cer-
vical stroma was observed on CET1WI. The patient
subsequently underwent total hysterectomy (TH) with
bilateral salpingo-oophorectomy (BSO) and pelvic
lymphadenectomy. The surgical specimen of the
uterus showed white gray polypoid mass filling the
endometrial cavity (Fig. 1b). Upon microscopic exam-
ination, the tumor with high cellularity and pattern-
less growth without glandular differentiation invaded
the full thickness of the lower uterine segment
(Fig. 1c) extending to the cervical stroma. The tumor
consisted of medium–sized monotonous cells with
brisk mitosis (5 per high-power field (HPF)) and atyp-
ical mitotic figures (Fig. 1d). Moderately differentiated
endometrioid adenocarcinoma component with squa-
mous differentiation comprised the major proportion
of the tumor mass of the uterine body and fundus,
which invaded more than one half of the myometrial
thickness. No lymph node (LN) metastasis was found.
Cytokeratin 8/18 (CK8/18) and pancytokeratin (CK
AE1/AE3) expressed both components but in different
patterns. In the UC component, they were expressed as
dot-like patterns, whereas they showed cytoplasmic ex-
pression in differentiated component (Figs. 1e, f ). Epithe-
lial membrane antigen (EMA), estrogen receptor (ER),
progesterone receptor (PR), E-cadherin, and PAX-8 were
expressed in the differentiated component alone (Table 2).
Based on the FIGO system, the patient had stage II. She
was recommended adjuvant external beam pelvic RT
(EBRT), but she refused. A month after the surgery, she
presented with difficulty in urination. Abdominal pelvic
computed tomography (CT) revealed multiple, large,
peritoneal seeding masses, and multiple lymph node
metastases in the external and internal iliac chains with
large amount of ascites which was positive for malignant
cells on cytologic examination. She died 7 weeks later after
surgery due to tumor lysis syndrome.
Case 2
A 54-year-old postmenopausal woman (BMI: 22.5 kg/m2)
was referred to our hospital after being diagnosed with
endometrioid carcinoma FIGO grade 3 on biopsy at a
local hospital. She experienced vaginal bleeding for
3 months. She had menopause at 51 year old hypertension
history. MRI showed a 5.0 × 3.6 cm lobulated mass filling
the endometrial cavity, which showed slightly high signal
intensity (SI) on T2-weighted imaging (T2WI) and
showed poor enhancement compared with the adjacent
myometrium (Fig. 2a). Mildly enlarged pelvic LNs were
noted in both external iliac areas. TH with BSO, pelvic
lymphadenectomy, and para-aortic lymphadenectomy
were performed. The mass was bulky and filled the entire
endometrial cavity on gross examination (Fig. 2b). Micro-
scopically, well-differentiated endometrioid adenocarcin-
oma and UC with abrupt transition were found between
them (Fig. 2c). The UC component showed a solid mono-
morphic discohesive cell growth, showing no differenti-
ation except for the presence of some rhabdoid cells
(Fig. 2d). The invasion depth was less than one half of the
myometrium, and LN metastasis was not observed. CK8/
18, CK AE1/AE3, and EMA showed diffuse cytoplasmic
expression in both components, and perinuclear cytokera-
tin dots were also observed in the UC component. The
ER, PR, E-cadherin, and PAX-8 expressions were recog-
nized in the differentiated component alone (Table 2). The
final FIGO stage was IA, and adjuvant treatment was not
performed. The patient has been disease-free for
19 months after the initial diagnosis.
Case 3
A 60-year-old postmenopausal woman (BMI: 25.3 kg/m2)
with a chief complaint of vaginal spotting for 1 year visited
a local gynecologic clinic. She had menopause at 52 years
old. Colposcopy showed necrotic tissue with bleeding at
the right vaginal wall, and she was referred to our hospital
for further evaluation. Ultrasonography showed an echo-
genic mass in the endometrial cavity. The MRI revealed a
7.2 × 3.5 cm lobulated mass extending to the right above
the endocervix (Fig 3a). The mass showed high SI on
T2WI and low SI on T1WI with heterogeneous enhance-
ment. Another 5 cm, elongated mass involving the lower
vagina was also found. Vaginal biopsy revealed poorly dif-
ferentiated carcinoma, and cytologic test of the endocervix
revealed adenocarcinoma. The patient underwent wide
cuff TH with BSO, and the separated additional vaginal
mass was not removed. The surgical specimen showed a
polypoid mass with necrosis and hemorrhage, which
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invaded more than one half of the myometrium of the
uterus (Fig. 3b), extending to the cervix. Most of the
tumor comprised discohesive cell growth with a solid
sheet pattern on microscopic examination, suggesting a
UC component. They were occasionally segregated by
delicate fibrovascular septa forming a vague alveolar pat-
tern (Fig. 3c). The UC component showed small amount
of myxochondroid stroma, reminiscent of cartilage
(Fig. 3d). A small proportion (10%) of tumor consisted of
low-grade endometrioid adenocarcinoma juxtaposed with
UC component. The histological finding of the UC com-
ponent was similar to that of the lesion in the vaginal wall,
suggesting vaginal metastasis (drop metastasis). ER and
PR were not expressed in both UC and differentiated
Table 1 Clinical and pathologic features of four patients with dedifferentiated endometrioid adenocarcinoma (DEAC) of uterus
Case 1 Case 2 Case 3 Case 4
Clinical features
Age at diagnosis, years 77 54 60 52


























MRI: 5.0 × 3.6 cm sized lobulated
mass filling endometrial cavity
with slightly high SI in T2WI
and poor enhancement than
adjacent myometrium
MRI: 7.2 × 3.5 cm sized
lobulated mass which
showed high SI on T2WI
and low SI on T1WI with
heterogeneous
enhancement
CT: 10 cm sized low
density mass in the
endometrial cavity
and cervical canal
Surgical management TH/BSO/PLND TH/BSO/PLND/PALND Wide cuff TH/BSO TH/BSO/PLND/PALND












Refused Not needed Chemotherapy (CDDP + ADR + CTX)





1 month None 1 month None
FIGO surgical stage II IA IIIB II
Clinical history Hypertension Hypertension Hypertension None
Family history None None Gastric cancer (mother) None
Status at last follow-up DOD (7 weeks) NED (19 months) DOD (10 months) NED (39 months)
Pathologic features
Tumor location Fundus, body,
lower uterine
segment, cervix




Tumor grade G2 (80%) + UC (20%) G1 (70%) + UC (30%) G1 (10%) + UC (90%) G2 (40%) + UC (60%)
Myometrial invasion Full thickness
of myometrium
<1/2 of myometrium <1/2 of myometrium >1/2 of myometrium
Lymphovascular space
invasion (LSI)
Present Present Present Present
Cervical stromal invasion Present Absent Present Present
Ovaries and fallopian
tubes
Unremarkable Unremarkable Unremarkable Unremarkable
CET1WI contrast-enhanced T1-weighted image; SI signal intensity; T2WI T2-weighted image; T1WI T1-weighted image; TH total hysterectomy; BSO bilateral
salpingo-oophorectomy; PLND pelvic lymph node dissection; PALND para-aortic lymph node dissection; EBRT external beam radiation therapy; ICR intracavitary
radiation; DOD die of disease; NED no evidence of disease; UC undifferentiated carcinoma; G1 FIGO grade 1 endometrioid adenocarcinoma; G2 FIGO grade 2
endometrioid adenocarcinoma; CDDP cisplatin; ADR adriamycin; PTX paclitaxel; CTX cyclophosphamide
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component on immunohistochemical staining (Table 2).
One month after the surgery, postoperative positron emis-
sion tomography-CT revealed multiple metastatic lymph-
adenopathies in para-aortic, retrocaval, paracaval, both
common and external iliac chains, and superficial inguinal
areas with bone metastasis. The patients was treated with
sequential chemoradiation therapy, which comprised of
chemotherapy (cisplatin + Adriamycin + cyclophospha-
mide) followed by EBRT, with a total dose of 50 Gy was
administered for 5 weeks to the whole pelvis, vagina, and
both inguinal lymph nodes, and high-dose intracavitary
radiotherapy (ICR) (20 Gy in fractions). She presented
with dyspnea 2 months after radiation therapy, and
clinical examination revealed lung metastasis. She died
3 weeks later (10 months after surgery).
Case 4
A 52-year-old nulligravid, perimenopausal woman (BMI
22.4 kg/m2) was admitted to our hospital for treatment
of leiomyoma, manifested as 10 cm low-density mass in
the endometrial cavity and cervical canal on pelvic CT at
a local clinic (Fig. 4a). She experienced intermittent vagi-
nal bleeding 3 years prior. During surgery, the surgeon
observed a 10 cm necrotic mass protruding through the
cervical canal, which seemed to fill the entire endomet-
rial cavity. Frozen section revealed malignancy. Surgical
stage was FIGO stage II, due to cervical stromal invasion.
Any enlarged lymph node was not recognized. Hence, the
patient was treated with bilateral salpingectomy with pelvic
and para-aortic lymph node dissection. The fungating mass
filling the entire endometrial cavity was recognized on gross
examination (Fig. 4b). The tumor comprised of conven-
tional endometrioid adenocarcinoma (FIGO grade 2) and
UC with sharp border between them (Fig. 4c). CK8/18, CK
AE1/AE3, and EMA were expressed focally as dot-like and
cytoplasmic pattern in UC component (Fig. 4d). PAX-8 was
diffusely expressed in both components (Table 2). The pa-
tient was treated with adjuvant EBRT in the whole pelvis
with a total dose of 50 Gy in 28 fractions followed by vagi-
nal cylinder ICR (20 Gy/4 fractions). No evidence of recur-
rence or progression of disease was found after 39 months
after surgery.
Discussion
Because DEAC has been recently recognized, the inci-
dence rate is not established. The incidence of undiffer-
entiated carcinoma is known to be 1 to 9% [4, 5]. In
several retrospective studies, 37 to 87% of UC were
admixed with endometrioid adenocarcinoma [3, 5, 6]. In
our institution, 2.6% of patients (four out of 155 pa-
tients) with endometrial carcinoma were diagnosed with
DEAC between 2013 and 2015.
A dualistic model, proposed by Bokhman [7] based on
clinical and epidemiological observations, has been
known to be correlated with endometrial carcinoma
classification based on histopathological subtypes. Pre-
dominant form of type 1 endometrial carcinoma is low-
grade endometrioid adenocarcinoma, whereas type II
encompasses high-grade endometrioid adenocarcinoma,
and most non-endometrioid histologic subtypes. How-
ever, increasing evidence supports that the binary classi-
fication is imperfect [8], and DEAC may be one of the
representative entities. Type I tumors are known to be
associated with unopposed estrogen stimulation,
whereas type II tumors are commonly described as es-
trogen independent. The established risk factors for type
Table 2 Results of immunohistochemical stains of the four cases
IHC stain Case 1 Case 2 Case 3 Case 4

























































Vimentin Focal Negative Diffuse Diffuse Diffuse Diffuse Diffuse Focal
ER Negative Positive Negative Positive Negative Negative Negative Positive
PR Negative Positive Negative Positive Negative Negative Negative Positive
E-cadherin Negative Diffuse Negative Focal Negative Diffuse, weakly Negative Diffuse
PAX-8 Negative Diffuse Negative Diffuse Negative Diffuse Diffuse Diffuse
Proportion of tumor cells are >50%, diffuse; 10 ~ 50%, focal; <10%, negative; EMA epithelial membrane antigen; ER estrogen receptor; PR progesterone receptor
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I endometrial carcinomas are obesity, unopposed estro-
gen therapy use, nulliparity, early menarche, late meno-
pause, oral contraceptive use, and smoking, whereas
little is known regarding the risk factors for type II tu-
mors. A recent study [9] showed that most classical
endometrial cancer risk factors were also associated with
type II tumors, suggesting that the etiology of type II tu-
mors may not be completely estrogen independent. In
the same context, three of four patients of our cases
were postmenopausal, older (≥54 year old) women, and
the other perimenopausal woman was nulliparous. Three
patients of our cases had hypertension as underlying dis-
ease. Giordano et al. [10] showed that the majority of
patients with malignant endometrial polyps had risk fac-
tors, such as hypertension, obesity, and unopposed es-
trogen therapy, for the development of endometrial
carcinoma.
Fig. 1 Case 1. (A1) Sagittal contrast-enhanced T1-weighted MRI shows
heterogeneously enhanced mass filling the endometrial cavity with
cervical stromal invasion. (A2) The tumor shows white infiltrative lesion
with necrosis involving lower uterine segment and uterine body,
extending to cervix. The UC component (A3, ×2.5) infiltrates the full
thickness of the lower uterine segment and arranged in patternless
with extensive necrosis and hemorrhage. The tumor (A4, ×400)
comprises monotonous cells with moderate pleomorphism, prominent
nucleoli, and high mitotic rates. Cytokeratin 8/18 (CK8/18) expressed as
perinuclear dots in the UC component (A5, ×400) and showed diffuse
cytoplasmic expression in differentiated component (A6, ×200)
Fig. 2 Case 2. (B1) Sagittal T2-weighted MRI shows a large polypoid
endometrial mass with superficial infiltration of myometrium. (B2) Gross
photograph shows a polypoid mass compacting the endometrial cavity.
Well-circumscribed round mass, submural leiomyoma is seen (arrow).
(B3, ×100) The tumor comprises moderately differentiated endometrioid
adenocarcinoma and UC with abrupt transition (arrows) between them.
(B4, ×400) The UC cell component shows discohesive rhabdoid feature
Fig. 3 Case 3. (C1) Sagittal contrast-enhanced T1-weighted MRI
shows a large polypoid mass lesion filling the endometrial cavity.
(C2) The tan polypoid mass involving more than one half of the
myometrium. (C3, ×200) A delicate fibrovascular septa separating
discohesive cells into vague alveolar nests are found. (C4, ×200)
Focal areas of UC component shows myxochondroid stroma with
embedded tumor cells, resembling the cartilage
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In all our cases, DEAC could not be diagnosed on bi-
opsy or curettage and imaging studies, but could only be
correctly diagnosed by pathological examination of the
surgical specimen. Two cases were initially diagnosed as
poorly differentiated carcinoma, and one case was diag-
nosed as FIGO grade 3 endometrioid adenocarcinoma
by endometrial biopsy or curettage. A recent study [11]
showed that preoperative endometrial biopsy or curet-
tage is sensitive overall for detecting endometrial cancer,
but sensitivity decreases with high-risk histology endo-
metrial cancer. In addition, interobserver reproducibility
in diagnosing high-grade endometrial carcinomas has
been known to be worse than that of low-grade tumors
[12]. Therefore, if preoperative examination suggests
high-grade endometrial carcinomas, the surgeon should
proceed to a more thorough surgical staging.
To correctly diagnose DEAC, recognizing the UC
component is important. Recent studies [5, 13] empha-
sized that there is reproducible, distinctive histological
features of UC, which are confirmed in all present cases.
Although histological findings of UC can overlap with
that of high-grade endometrioid adenocarcinoma, differ-
ences were found between them. In UC, tumor cells lack
intercellular cohesion and arranged in patternless solid
sheets without gland formation, which were occasionally
admixed with rhabdoid cells. In contrast, high-grade
endometrioid adenocarcinoma has at least a foci of
gland formation of cohesive cells with rare or no rhab-
doid cells. In addition, the tumor cells of UC in our
cases also tended to have larger nuclei with more prom-
inent nucleoli than conventional endometrioid adenocar-
cinoma. When UC are juxtaposed with low-grade
endometrioid adenocarcinoma, such as in DEAC, a
sharp boundary is noted between them, whereas a seam-
less transition from glandular component to solid area is
observed in high-grade endometrioid adenocarcinoma.
Immunochemical studies are also helpful in making a
differential diagnosis. Among the epithelial markers,
EMA and CK18 are known to be strongly and diffusely
stained in the solid area of high-grade endometrioid car-
cinoma, but are focal or weak in the UC component [6].
In the previous case reports, expression of EMA in the
UC components showed relatively inconsistency
(Table 3), and our cases also showed variable expression
of EMA and CK18 (Table 2). However, we found that
expression of EMA and CK18 were perinuclear dot-like
pattern in UC component, whereas diffuse cytoplasmic
pattern in differentiated component in all cases. Rama-
lingam et al. [14] suggested PAX-8 to be the most effect-
ive immunomarker to distinguish UC from the solid
component of either endometrioid carcinoma or serous
carcinoma. In the present study, three of 4 cases
expressed PAX-8 in the differentiated component alone,
whereas the other one also expressed PAX-8 in the UC
component. ER, PR, and E-cadherin are known to be
retained in conventional endometrioid adenocarcinoma
[6, 15, 16], but not in the UC, which were consistent with
our cases. Therefore, perinuclear dot-like staining of cyto-
keratin and EMA, loss of expression of PAX-8, ER, PR,
and E-cadherin would be helpful to distinguish UC from
conventional endometrioid adenocarcinoma.
Differentiating between them is important because
DEACs have fulminant clinical outcomes and poorer
prognosis than high-grade endometrioid carcinoma. Sev-
eral reports of DEAC cases with clinical feature, are
summarized in Table 3.
In our cases, the proportion of UC component ranged
from 20 to 90% (Table 1), which did not seem to be as-
sociated with clinical outcomes. In addition, the involve-
ment to the lower uterine segment and cervix occurred
in the UC component in all cases.
The morphologic appearance of DEACs suggest very
broad differential diagnoses, including not only high-
grade endometrioid adenocarcinoma, but also unclassi-
fied sarcomas, malignant mixed Müllerian tumors
(MMMT), and rhabdoid tumor.
The UC component in DEAC may be negative or focal
positive for keratin in immunohistochemical staining,
and it can be misdiagnosed as sarcoma. Most sarcomas
in the uterus comprise spindle cells with muscular dif-
ferentiation and seldom comprise epithelioid cells only.
Immunostaining with markers for muscular differenti-
ation, such as desmin, caldesmon, and SMA may help to
Fig. 4 Case 4. (D1) Sagittal contrast-enhanced CT shows a bulky
hypodense mass filling the endometrial cavity. (D2) The large outbulging
mass with friable surface. (D3, ×2.5) A sharp border between differentiated
and UC component and EMA (D4, ×2.5 and ×400) shows strong
cytoplasmic expression in the former and focal dot and cytoplasmic
expression in the latter
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distinguish between them because DEACs are negative
for these markers.
MMMT is a biphasic tumor that usually contains car-
cinoma and sarcomatous components. However, both
components are high-grade in MMMT, whereas the
gland-forming component is low-grade (grade 1/2), and
no mesenchymal component is found in DEACs. Case 3
had focal areas with myxoid stroma mimicking heterol-
ogous component of MMMT. MMMTs typically occur
in older women, whereas DEACs may occur in young
patients. Moreover, these two entities may have distinct
biology; MMMT is usually not associated with microsat-
ellite instability, however, a proportion of DEACs appear
to be associated with microsatellite instability [17].
Our cases had various proportions of rhabdoid cells,
and if these are prominent, DEACs need to be differenti-
ated from extrarenal malignant rhabdoid tumor. Unlike
DEACs, rhabdoid tumors are not associated with a well-
differentiated endometrioid carcinoma.
Conclusion
In summary, DEAC is a rare and recently defined entity,
which has distinct histological and immunohistochemi-
cal features and should not be underdiagnosed as con-
ventional endometrioid adenocarcinoma. Furthermore,
among the endometrioid type 2 tumors, UC including
DEAC should be further categorized because of their
worse clinical and biological behavior.
Abbreviations
BMI: Body mass index; BSO: Bilateral salpingo-oophorectomy;
CET1WI: Contrast-enhanced T1-weighted images; CK AE1/
AE3: Pancytokeratin; CK8/18: Cytokeratin 8/18; DEAC: Dedifferentiated
endometrioid adenocarcinoma; EBRT: External-beam pelvic RT;
EMA: Epithelial membrane antigen; ER: Estrogen receptor; FIGO: Federation
of Obstetrics and Gynecology; HPF: High-power field; ICR: Intracavitary
radiotherapy; LN: Lymph node; PR: Progesterone receptor; TH: Total
hysterectomy; UC: Undifferentiated carcinoma
Acknowledgements
The authors declare that there are no acknowledgements.
Availability of data and materials
All the data on which the conclusions of this case report are based are
included in this manuscript.
Author’s contributions
JH collected the data and authored the manuscript. EY and SE contributed to
the data analysis and shaping of the manuscript. SY performed the surgical
procedure and also contributed the data analysis. AW conceived the given
instructions for acquisition of data, outlined, and contributed to the shaping of
the manuscript. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for the publication
of this case report and any accompanying images.
Ethics approval and consent to participate
Ethical approval is obtained from the Institutional Review Boards of St. Mary’s
Hospital (Application number: KC16ZISE0659). Consents of the patients were
obtained to participate to the presentation of this report.
Author details
1Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of
Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu,
Seoul 06591, Republic of Korea. 2Department of Obstetrics and Gynecology,
Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of
Korea, Seoul, Republic of Korea. 3Department of Radiology, Seoul St. Mary’s
Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Republic of Korea.
Received: 23 September 2016 Accepted: 23 December 2016
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of
tumours of female reproductive organs. 4th ed. Lyon: International Agency
for Research on Cancer; 2014.
3. Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade
endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma:
a new type of dedifferentiated carcinoma? Int J Gynecol Pathol. 2006;25:52–8.
4. Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In:
Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 5th ed.
New York: Springer-Verlag; 2002. p. 501–59.
5. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG.
Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29:
1316–21.
6. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian
carcinomas with undifferentiated components: clinically aggressive and
frequently underrecognized neoplasms. Mod Pathol. 2010;23:781–9.
7. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol
Oncol. 1983;15:10–7.
8. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma:
more than two types. Lancet Oncol. 2014;15:e268–78.
9. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I
and II endometrial cancers: have they different risk factors? J Clin Oncol.
2013;31:2607–18.
10. Giordano G, Gnetti L, Merisio C, Melpignano M. Postmenopausal status,
hypertension and obesity as risk factors for malignant transformation in
endometrial polyps. Maturitas. 2007;56:190–7.
11. Kanis MJ, Rahaman J, Moshier EL, Zakashansky K, Chuang L, Kolev V. Detection
and correlation of pre-operative, frozen section, and final pathology in high-
risk endometrial cancer. Eur J Gynaecol Oncol. 2016;37:338–41.
12. Thomas S, Hussein Y, Bandyopadhyay S, Cote M, Hassan O, Abdulfatah E, et
al. Interobserver variability in the diagnosis of uterine high-grade
endometrioid carcinoma. Arch Pathol Lab Med. 2016;140:836–43.
13. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the
endometrium: a review. Pathology. 2007;39:134–8.
14. Ramalingam P, Masand RP, Euscher ED, Malpica A. Undifferentiated
carcinoma of the endometrium: an expanded immunohistochemical
analysis including PAX-8 and basal-like carcinoma surrogate markers. Int J
Gynecol Pathol. 2016;35:410–8.
15. Li Z, Zhao C. Clinicopathologic and immunohistochemical characterization
of dedifferentiated endometrioid adenocarcinoma. Appl Immunohistochem
Mol Morphol. 2016;24:562–8.
16. Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ,
Tafe LJ, et al. ZEB1 overexpression associated with E-cadherin and
microRNA-200 downregulation is characteristic of undifferentiated
endometrial carcinoma. Mod Pathol. 2013;26:1514–24.
17. Garg K, Leitao Jr MM, Kauff ND, Hansen J, Kosarin K, Shia J, et al. Selection of
endometrial carcinomas for DNA mismatch repair protein
immunohistochemistry using patient age and tumor morphology enhances
detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33:925–33.
18. Shen Y, Wang Y, Shi Y, Liu J, Liu Y. Clinicopathologic study of endometrial
dedifferentiated endometrioid adenocarcinoma: a case report. Int J Clin Exp
Pathol. 2012;5:77–82.
Han et al. World Journal of Surgical Oncology  (2017) 15:17 Page 8 of 9
19. Vita G, Borgia L, Di Giovannantonio L, Bisceglia M. Dedifferentiated
endometrioid adenocarcinoma of the uterus: a clinicopathologic study of a
case. Int J Surg Pathol. 2011;19:649–52.
20. Wu ES, Shih Ie M, Diaz-Montes TP. Dedifferentiated endometrioid
adenocarcinoma: An under-recognized but aggressive tumor? Gynecol
Oncol Case Rep. 2013;5:25–7.
21. Berretta R, Patrelli TS, Faioli R, Mautone D, Gizzo S, Mezzogiorno A, et al.
Dedifferentiated endometrial cancer: an atypical case diagnosed from
cerebellar and adrenal metastasis: case presentation and review of literature.
Int J Clin Exp Pathol. 2013;6:1652–7.
22. Park SY, Park MH, Ko HS, Cha EJ, Sohn JS, Jung US, et al. Dedifferentiated
endometrioid adenocarcinoma of the uterus: highly aggressive and poor
prognostic tumor. Korean J Pathol. 2014;48:327–30.
23. Soyama H, Takano M, Miyamoto M, Kato M, Goto T, Furuya K.
Dedifferentiated endometrioid adenocarcinoma of the uterus: a case report.
Eur J Gynaecol Oncol. 2016;37:426–9.
24. Rabban JT. Dedifferentiated endometrial carcinoma: An aggressive tumor
that may morphologically mimic lower-grade endometrioid
adenocarcinoma. AJSP: Reviews & Reports. 2016;21:57–72.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Han et al. World Journal of Surgical Oncology  (2017) 15:17 Page 9 of 9
